Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

1.8%

14 terminated/withdrawn out of 776 trials

Success Rate

91.0%

+4.5% vs industry average

Late-Stage Pipeline

11%

86 trials in Phase 3/4

Results Transparency

4%

5 of 142 completed trials have results

Key Signals

136 recruiting5 with results10 withdrawn

Enrollment Performance

Analytics

N/A
216(42.6%)
Phase 2
149(29.4%)
Phase 4
49(9.7%)
Phase 1
47(9.3%)
Phase 3
37(7.3%)
Early Phase 1
9(1.8%)
507Total
N/A(216)
Phase 2(149)
Phase 4(49)
Phase 1(47)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (776)

Showing 20 of 776 trials
NCT07640997Recruiting

Real-world Study of Aflibercept 8 mg in nAMD

Role: lead

NCT07176754Not ApplicableActive Not Recruiting

TNF-α Antagonists Mitigate Systemic Inflammatory Response After Cardiac Arrest.

Role: collaborator

NCT07598084Not Yet Recruiting

Non-Contrast Breast MRI Diagnosis and Risk Stratification Using DWI-Generated Synthetic Contrast Enhancement

Role: lead

NCT07632664Not ApplicableRecruiting

Clinical Study of a New Treatment Model for Elderly Lung Cancer Patients

Role: lead

NCT07629544Phase 3Not Yet Recruiting

A Study of DA-302168S in Participants With Overweight/Obesity

Role: collaborator

NCT07629947Not ApplicableNot Yet Recruiting

Peripheral Blood Versus Bone Marrow Plus Peripheral Blood Grafts for Haploidentical Transplantation in Severe Aplastic Anemia

Role: lead

NCT07359040Recruiting

Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer

Role: lead

NCT07564518Not Yet Recruiting

Application of FreeStyle Libre 2 for Evaluating Glycemic Variability Characteristics in Patients With Extreme Glucose Metabolism Phenotypes

Role: lead

NCT07620431Not Yet Recruiting

Neoadjuvant Radiotherapy and Surgery for High-Risk Localized Ewing Sarcoma

Role: lead

NCT07617740Early Phase 1Recruiting

IASO207 Injection for Active Refractory Systemic Lupus Erythematosus (SLE)

Role: lead

NCT07617285Phase 1Recruiting

Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML

Role: lead

NCT07517484Not ApplicableRecruiting

Light and Anesthesia

Role: lead

NCT07608640Not Yet Recruiting

Management of Age-Related Auditory Decline and Early Warning of Its Co-occurring Dementia

Role: collaborator

NCT07167342Phase 4Recruiting

The Effect of Oral Clostridium Butyricum on the Recurrence After Colonoscopic Resection of Colorectal Adenoma

Role: collaborator

NCT07588594Not ApplicableRecruiting

Thiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic Leukemia

Role: lead

NCT05129904Active Not Recruiting

Precise Profiling of Liver Disease Patients With DPMAS Therapy, Treating Optimal Patients and Achieving Hard Endpoint (PADSTONE Study)

Role: collaborator

NCT07600164Phase 4Not Yet Recruiting

Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer

Role: lead

NCT07597395Phase 3Not Yet Recruiting

ATRA for Management of Primary ITP

Role: lead

NCT07593365Not ApplicableNot Yet Recruiting

Clinical Application of Vagus Nerve Stimulation Combined With Immunoregulatory T Cells in Alleviating Aromatase Inhibitor-Induced Pain

Role: lead

NCT07002346Phase 3Recruiting

INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma

Role: collaborator